Alprostadil/Papaverine Hydrochloride/Phentolamine Mesylate/Atropine Sulfate Inje Supply Disruption — Fusion IV Pharmaceuticals, In
Alprostadil/Papaverine Hydrochloride/Phentolamine Mesylate/Atropine Sulfate Inje Supply Disruption — Fusion IV Pharmaceuticals, In is one of 9,000 drug supply records in the DrugSupply dataset. Key details — Drug name: Alprostadil/Papaverine Hydrochloride/Phentolamine Mesylate/Atropine Sulfate Inje; Manufacturer: Fusio
| Drug name | Alprostadil/Papaverine Hydrochloride/Phentolamine Mesylate/Atropine Sulfate Inje |
|---|---|
| Manufacturer | Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical |
| Recall/Disruption reason | Lack of Assurance of Sterility |
| Risk classification | Moderate Risk — Temporary Health Consequence |
| Status | Terminated |
| Record type | Enforcement/Recall |
| Recall number | D-0934-2020 |
| Initiation date | 20200115 |
| Quantity affected | N/A |
| Dosage form | Drugs |
🔍 Search all drug supply records →
$1199/mo
Try DrugSupply →